Clinical Trials Browser

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

NCT04471974 2025-07-22

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Phase 2 Active not recruiting

61 enrolled 12 charts

Breast

Breast Neoplasms

NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Phase 2 Active not recruiting

50 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02446405 2025-02-06

ENZAMET

Phase 3 Active not recruiting

1,125 enrolled

Genitourinary

Prostatic Neoplasms

NCT02685397 2024-12-04

PCS IX

Phase 2/3 Active not recruiting

102 enrolled

Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT00268476 2023-04-18

STAMPEDE

Phase 2/3 Active not recruiting

11,992 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

EvoPAR-PR01

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

ArtemisPRO

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

ENZARAD

MEVPRO-1

IMbrella B

TALAPRO-2

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

China ARCHES

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

CASPAR

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

SPLASH

STEEL

PROSTEP-002

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

CONTACT-02

PETRANHA

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

ARACOG

CDK4i

PEACE III

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

PROTRACT

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

KEYNOTE-641

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

ENZAMET

PCS IX

STAMPEDE